ENZO BIOCHEM INC. COMMON STOCK ($0.01 PAR VALUE)

ENZO BIOCHEM TO PRESENT AT THE KEYBANC CAPITAL MARKETS' LIFE SCIENCES & MEDTECH INVESTOR FORUM

17 Mar 2021 16:15:00 By Nasdaq GlobeNewswire

Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates

15 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Enzo Biochem to Participate in the H.C. Wainwright Global Life Sciences Conference

04 Mar 2021 08:00:04 By Nasdaq GlobeNewswire

Enzo Biochem to Report Second Quarter 2021 Financial Results on Monday, March 15

01 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Enzo Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin

03 Feb 2021 08:29:57 By Nasdaq GlobeNewswire

ENZO BIOCHEM’S BOARD OF DIRECTORS FORMS NEW CORPORATE DEVELOPMENT AND PLANNING & SUCCESSION COMMITTEES

20 Jan 2021 08:13:46 By Nasdaq GlobeNewswire

ENZO BIOCHEM TO PARTICIPATE IN THE LIFESCI PARTNERS 10TH ANNUAL HEALTHCARE CORPORATE ACCESS EVENT

05 Jan 2021 08:00:02 By Nasdaq GlobeNewswire

ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR TESTING POOLED SAMPLES ON THREE PLATFORMS INCLUDING COMPANY’S GENFLEX™ PROPRIETARY SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2

04 Jan 2021 07:00:00 By Nasdaq GlobeNewswire